Efficacy and Safety of Suprachoroidal Triamcinolone Acetonide in Center Involving Diabetic Macular Edema in Pseudophakic Patients
DOI:
https://doi.org/10.52206/jsmc.2025.15.1.948Keywords:
Diabetic macular edema, suprachoroidal, triamcinolone acetonideAbstract
Background: Diabetic macular edema is the common cause of decrease vision in diabetics. The treatment of diabetic macular edema is challenging and the options available are laser, intravitreal anti-VEGF and steroids or combination of these treatment modalities.
Objective: The objective of the study is to determine the efficacy of suprachoroidal triamcinolone alone in the treatment of diabetic macular edema.
Materials and Methods: This quasi-experimental study was carried out in the department of Ophthalmology of Khyber Teaching Hospital, Peshawar from August 2023 till February 2024. Pseudophakic patients with center involving diabetic macular edema on optical coherence tomography were enrolled in the study by consecutive convenient sampling method. Patients with history of glaucoma, phakic patients, those with corneal opacity, vitreous hemorrhage, proliferative diabetic retinopathy, macular edema from causes other than diabetes, history of pan-retinal photocoagulation for proliferative diabetic retinopathy were excluded from the study. The enrolled patients were given suprachoroidal triamcinolone acetonide injection of 0.1 ml (4mg) using a specialized syringe in the operating room.
Results: Total of 42 patients were recruited in the study. The mean age of the participants were 59.12 + 8.15 years. One-month post-injection there was statistically significant improvement in visual acuity from pre-treatment level with a p-value 0.001. No statistically significant changes were detected in IOP in pre-treatment and post-treatment suprachoroidal triamcinolone acetonide injection (p-value 0.21). There was statistically significant decrease in the central macular thickness in post-treatment patients 383.68 + 62.64 and 324.14 + 57.96 respectively with a P-value 0.02.
Conclusion: Suprachoroidal triamcinolone acetonide injection is associated with improvement in visual acuity and reduction in central macular thickness without significant increase in intraocular pressure in patients with diabetic macular edema.
Keywords: Central macular thickness, Macular edema, suprachoroidal, Triamcinolone acetonide.
References
Dugalic S, Petronijevic M, Vasiljevic B, Todorovic J, Stanisavljevic D, Jotic A. Trends of the prevalence of pre-gestational diabetes in 2030 and 2050 in Belgrade cohort. Int J Environ Res Public Health 2022;19(11):6517. https://doi.org/10.3390/ijerph19116517
Azeem S, Khan U, Liaqat A. The increasing rate of diabetes in Pakistan: A silent killer. Ann Med Surg 2022;79:103-8. https://doi.org/10.1016/j.amsu.1022.103901
Cooper OE, Taylor DJ, Crabb DP, Sim DA, McBain H. Psychological, social and everyday visual impact of diabetic macular edema and diabetic retinopathy: A systematic review. Diabet Med 2020;37(6): 924-33. https://doi.org/10.1111/dme.14125
Everett LA, Paulus YM. Laser therapy in the treatment of diabetic retinopathy and diabetic macular edema. Curr Diab Rep 2021;6:21-9. https://doi.org/10.1007/s11892-021-01403-6
Blinder KJ, Dugel PU, Chen S, Jumper JM, Walt JG, Hollander DA, et al. Anti-VEGF treatment of diabetic macular edema in clinical practice: effectiveness and patterns of use (ECHO Study Report 1). Clin Ophthalmol 2017;11:393–401. https://doi.org/10.2147/OPTH.S128509
He Y, Ren XJ, Hu BJ, Lam WC, Li XR. A meta-analysis of the effect of a dexamethasone intravitreal implant versus intravitreal anti-vascular endothelial growth factor treatment for diabetic macular edema. BMC Ophthalmol 2018;18(1): 121-6. https://doi.org/10.1186/s12886-018-0779-1
Patil NS, Mihalache A, Hatamnejad A, Popovic MM, Kertes PJ, Muni RH. Intravitreal steroids compared with anti-VEGF treatment for diabetic macular edema: A meta-analysis. Ophthalmol Retina 2023; 7(4):289-99. https://doi.org/10.1016/j.oret.2022.10.008
Zakaria YG, Salman AG, Said AMA, Abdelatif MK. Suprachoroidal versus intravitreal triamcinolone in the treatment of diabetic macular edema. Clin Ophthalmol 2022;16:733-46. https://doi.org/10.37939/jrmc.v27i4.2430
Habot-Wilner Z, Noronha G, Wykoff CC. Suprachoroidally injected pharmacological agents for the treatment of chorio-retinal diseases:a targeted approach. Acta Ophthalmol 2019;97(5): 460–472. https://doi.org/10.1111/aos.14042
Wu KY, Fujioka JK, Gholamian T, Zaharia M, Tran SD. Suprachoroidal Injection: A novel approach for targeted drug delivery. Parmaceuticals 2023;16(9): 1241-5. https://doi.org/10.3390/ph16091241
Chiang B, Jung JH, Prausnitz MR. The suprachoroidal space as a route of administration to the posterior segment of the eye. Adv Deliv Rev 2018;126:58-66. https://doi.org/10.1016/j.addr.2018.03.001
Campochiaro PA, Wykoff CC, Brown DM, Boyer DS, Barakat M, Taraberelli D et al. Tanzanite study group. Suprachoroidal triamcinolone acetonide for retinal vein occlusion: Results of the Tanzanite study. Ophthalmol Retina 2018;2(4):320-8. https://doi.org/10.1016/j.oret.2017.07.013
Syed AN, Safdar M, Abbas S. Systemic predictors of diabetic macular edema in patients visiting tertiary hospital. Pak J Surg 2020;36(4):343-8. https://doi.org/10.53350/pjmhs22162744
Hanif J, Iqbal K, Perveen F, Arif A, Iqbal RN, Jameel F et al. Safety and efficacy of suprachoroidal injection of triamcinolone in treating macular edema seconday to non-infectious uveitis. Cureus 2021. 30;13(11):e20038. https://doi.org/10.7759/cureus.20038
Yu QS, Tsuboi K, Guo Y, Wang J, Flaxel CJ, Bailey ST et al. Comparison of central macular fluid volume with central subfield thickness in patients with diabetic macular edema using optical coherence tomography angiography. JAMA Ophthalmol 2021; 139(7):734-41. https://doi.org/10.1001/jamaophthalmol.2021.1275
Tayyab H, Ahmed SN, Sadiq MA. Efficacy and safety of suprachoroidal triamcinolone acetonide in cases of resistant diabetic macular edema. Pak J Med Sci 2020;36(2):42-7.
Nawar AE. Effectiveness of Suprachoroidal injection of triamcinolone acetonide in resistant diabetic macular edema using a modified microneedle. Clin Ophthalmol 2022;16:3821-31. https://doi.org/10.2147/OPTH.S391319
Fazel F, Malekahmadi M, Feizi A, Oliya B, Tavakoli M, Fazel M. Suprachoroidal injection of triamcinolone acetonide plus intravitreal bevecizumab in diabetic macular edema: a randomized pilot trial. BMC Ophthalmol 2023; 23:40-7. https://doi.org/10.1186/s12886-023-02790-y
Tabl AA, Soliman TT, Elsayed MA, Tabl MA. A randomized trial comparing suprachoroidal and intravitreal injection of triamcinoloone acetonide in refractory diabetic macular edema due to epiretinal membrane. J Ophthalmol 2022;7:254-8. https://doi.org/10.1155/2022/7947710
Muslim I, Chaudhry N, Javed RM. Effect of suprachoroidal triamcinolone injection on best corrected visual acuity and central retinal thickness in patients with macular edema secondary to retinal vein occlusion. Pak J Ophthalmol 2022;38(1): 67-70. https://doi.org/10.36351/pjo.v38i1.1347
Ghazanfar AS, Khowaja AH, Tayyab H. Effect of suprachoroidal triamcinolone on intraocular pressure: s systematic review and metanalysis. Ther Adv Ophthalmol 2024;5:1625158414 241228671. https://doi.org/10.1177/25158414241228671
Additional Files
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 The authors retain the copyrights. Authors are permitted and encouraged to post their work online (e.g. in institutional repositories or on their website), as it can lead to productive exchanges, as well as greater citation of published work.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Readers may “Share-copy and redistribute the material in any medium or format” and “Adapt-remix, transform, and build upon the material”. The readers must give appropriate credit to the source of the material and indicate if changes were made to the material. Readers may not use the material for commercial purpose. The readers may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
